Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich’s Genous™ Bio-engineered R stent™ Compared to Drug-Eluting Stents.
Stents
Boston Scientific Welcomes Launch of Syntax Score Website
Boston Scientific Corporation today welcomed the launch of a new website, www.syntaxscore.com, dedicated to the understanding and use of the SYNTAX Score™, a novel angiographic tool used to measure the complexity of coronary artery disease.
Endeavor Drug-Eluting Stent is First to Receive CE Mark for Treating Acute Coronary Syndrome
Medtronic, Inc., today announced that its Endeavor drug-eluting stent (DES) is the first and only coronary stent to have received CE Mark approval for treating patients with acute coronary syndrome.
Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
Boston Scientific Corporation today announced the launch of the platinum chromium TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in select markets worldwide.
NEVO Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus Liberte Stent in Pivotal Clinical Trial
At six months, the NEVO™ Sirolimus-eluting Coronary Stent, incorporating RES Technology™, was superior to the Taxus® Liberte® Stent in reducing tissue growth within the stent that can potentially lead to repeat procedures, in new clinical study results released today.
Innovative Stent Manufacturer XTENT Plans To Close Business After Failing to Find Buyer
XTENT, maker of an innovative stent that received the European CE Mark just two months ago, is closing its doors after failing to find a partner or buyer, a goal first announced in January.
Article Reports Fewer Repeat Procedures With Boston Scientific’s TAXUS® Liberte® Stent
Journal of American College of Cardiology reports fewer repeat procedures with Boston Scientific’s TAXUS® Liberte® Paclitaxel-Eluting Stent compared to patients treated with ‘olimus-based drug-eluting stents.
Bolton Medical Obtains CE Mark for the New RELAY Plus Thoracic Stent-Graft Delivery System
At the recent Charing Cross Symposium in London, Bolton Medical announced the launch of a new and further improved delivery system: RELAY Plus.
Abbott Initiates U.S. Study of Absolute Pro™ Peripheral Stent System for Iliac Artery Disease
Abbott today announced the initiation of MOBILITY, a clinical trial studying the safety and efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in patients with iliac artery disease.
Medtronic Announces International Market Release of Driver Sprint RX Coronary Stent System
Medtronic, Inc. today began the international launch of the Driver Sprint RX Coronary Stent System, which received the CE Mark in February 2009 and is planned to be commercially available in more than 100 countries worldwide.
Appeals Court Affirms That J&J Stents Infringe Boston Scientific Patent
Boston Scientific Corporation announced today that the Court of Appeals for the Federal Circuit issued a decision in the Company’s stent litigation with Johnson and Johnson.
Medtronic’s Endeavor Stent Shows Consistent And Sustained Safety And Effectiveness Benefits At Two Years
New data released at the 2009 American College of Cardiology meeting demonstrated exceptional long-term safety and effectiveness results for the Endeavor drug-eluting coronary stent from Medtronic, Inc.
Drug-Coated Stents Lower Risk Of Heart Attack And Death
Heart disease patients 65 and older who receive stents coated with medicine are more likely to survive and less likely to suffer a heart attack than people fitted with bare metal stents, according to a new study.
Abbott Advances its Revolutionary Fully Bioabsorbable Drug Eluting Stent with Initiation of Next Phase of Clinical Trial
Abbott today announced the initiation of the next phase of the ABSORB clinical trial to evaluate the safety and performance of the company’s fully bioabsorbable drug eluting coronary stent.
XTENT Receives CE Mark Approval for CUSTOM NX ® Drug-Eluting Stent System
XTENT, Inc. today announced that it has received CE Mark approval for its CUSTOM NX drug-eluting stent (DES) System.
‘New Class’ Of Coronary Stent Shows Sustained 12-Month Benefit
The CATANIA™ Coronary Stent System with NanoThin Polyzene®-F offers sustained benefit in the treatment of de novo coronary lesions and maximizes endothelialization, while reducing restenosis, thrombogenicity, and the need for long-term dual-antiplatelet therapy.